Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Edenfield

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Cancers|June 10, 2022
<i>KIT</i> Mutations Correlate with Higher Galectin Levels and Brain Metastasis in Breast and Non-Small Cell Lung CancerAvery T Funkhouser, Alexander M Strigenz, Bailey B Blair, et al.
Leukemia|October 8, 2015
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromesG Garcia-Manero, S D Gore, S Kambhampati, et al.
Cancer Chemotherapy and Pharmacology|June 27, 2023
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label studyMats Någård, Mei-Lin Ah-See, James Strauss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2015
Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate CancerBruce Montgomery, Mario A Eisenberger, Matthew B Rettig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical TrialStephen R Rapp, L Doug Case, Ann Peiffer, et al.
Blood|February 27, 2019
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignanciesAndres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, et al.
Cancer|April 23, 2013
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 studyJeffrey R Infante, Tony R Reid, Allen L Cohn, et al.
Cancer Chemotherapy and Pharmacology|February 17, 2021
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancerChao Li, Lowell Hart, Taofeek K Owonikoko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2012
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinomaRobert J Motzer, Thomas E Hutson, Mark R Olsen, et al.
British Journal of Cancer|October 8, 2014
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumoursI Brana, R Berger, T Golan, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Cancers|June 10, 2022
<i>KIT</i> Mutations Correlate with Higher Galectin Levels and Brain Metastasis in Breast and Non-Small Cell Lung CancerAvery T Funkhouser, Alexander M Strigenz, Bailey B Blair, et al.
Leukemia|October 8, 2015
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromesG Garcia-Manero, S D Gore, S Kambhampati, et al.
Cancer Chemotherapy and Pharmacology|June 27, 2023
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label studyMats Någård, Mei-Lin Ah-See, James Strauss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2015
Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate CancerBruce Montgomery, Mario A Eisenberger, Matthew B Rettig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical TrialStephen R Rapp, L Doug Case, Ann Peiffer, et al.
Blood|February 27, 2019
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignanciesAndres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, et al.
Cancer|April 23, 2013
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 studyJeffrey R Infante, Tony R Reid, Allen L Cohn, et al.
Cancer Chemotherapy and Pharmacology|February 17, 2021
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancerChao Li, Lowell Hart, Taofeek K Owonikoko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2012
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinomaRobert J Motzer, Thomas E Hutson, Mark R Olsen, et al.
British Journal of Cancer|October 8, 2014
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumoursI Brana, R Berger, T Golan, et al.
Pageof 4